Dynamic Contrast-Enhanced Magnetic Resonance Imaging as a Pharmacodynamic Biomarker for Pazopanib in Metastatic Renal Carcinoma

Clinical Genitourinary Cancer - United States
doi 10.1016/j.clgc.2016.08.011
Full Text
Abstract

Available in full text

Categories
OncologyUrology
Date
Authors
Publisher

Elsevier BV

Related search

Dynamic Contrast-Enhanced Magnetic Resonance Imaging as a Biomarker for Prediction of Radiation-Induced Neurocognitive Dysfunction

Clinical Cancer Research
Cancer ResearchOncology
2009English

Contrast Agents in Dynamic Contrast-Enhanced Magnetic Resonance Imaging

Oncotarget
Oncology
2017English

Dynamic Contrast-Enhanced Magnetic Resonance Imaging of Ocular Melanoma as a Tool to Predict Metastatic Potential

Journal of Computer Assisted Tomography
Nuclear MedicineRadiologyImaging
2017English

Dynamic Contrast-Enhanced Magnetic Resonance Imaging of OATP Dysfunction in Diabetes

Diabetes
Internal MedicineEndocrinologyMetabolismDiabetes
2018English

Dynamic Contrast-Enhanced Magnetic Resonance Imaging and Pharmacokinetic Models in Prostate Cancer

European Radiology
MedicineNuclear MedicineRadiologyImaging
2010English

Techniques and Applications of Dynamic Contrast Enhanced Magnetic Resonance Imaging in Cancer

2014English

Assessment of the Dynamic Range in Dynamic Contrast-Enhanced Magnetic Resonance Imaging Breast Examinations

Breast Cancer Research
Cancer ResearchOncology
2012English

The Use of Signal Phase in Dynamic Contrast-Enhanced Magnetic Resonance Imaging

English

Imaging Tumor Vascular Heterogeneity and Angiogenesis Using Dynamic Contrast-Enhanced Magnetic Resonance Imaging

Clinical Cancer Research
Cancer ResearchOncology
2007English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy